title: Cutaneous leishmaniasis in a patient receiving infliximab.
abstract: Leishmaniasis is endemic in the Mediterranean region, and the prevalence of latent infection in this area is high. Treatment with tumour necrosis factor (TNF) antagonists represents a major breakthrough in the treatment of several inflammatory diseases, including psoriasis. Reports describing opportunistic leishmaniasis in European patients treated with TNF-α antagonist drugs are rapidly accumulating. We describe a case of cutaneous leishmaniasis in a patient treated with infliximab and corticosteroids.
authors.affiliation: Department of Infectious Diseases, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain. maliht_1@hotmail.com
authors.forename: Alicia
authors.initials: A
authors.lastname: Hernández-Torres
authors.forename: Elisa
authors.initials: E
authors.lastname: García-Vázquez
authors.forename: José
authors.initials: J
authors.lastname: Frías-Iniesta
authors.forename: José Antonio
authors.initials: JA
authors.lastname: Herrero-Martínez
authors.forename: Joaquín
authors.initials: J
authors.lastname: Gómez-Gómez
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000069285:Infliximab; D016773:Leishmaniasis, Cutaneous / Q000175:diagnosis* / Q000473:pathology; D008297:Male; D019083:Mediterranean Region; D008875:Middle Aged; D013256:Steroids / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D013256:Steroids; D000069285:Infliximab